https://scitechdaily.com/new-hope-for-high-risk-prostate-cancer-promising-immunotherapy-agent-proven-to-be-safe/
0
0
4/26/23 at 4:40am
Organization
SciTechDaily
Authors
According to a phase 2 study conducted by the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, the monoclonal antibody enoblituzumab is deemed safe for use in men with aggressive prostate cancer and has the poten…
Create an account
or login to join the discussion